This preclinical study investigated how a short-term risperidone treatment in adolescence impacts antipsychotic response to olanzapine and clozapine in adulthood. Antipsychotic effect was indexed by a drug's suppressive effect on avoidance responding in a rat conditioned avoidance response (CAR) model. Male adolescent Sprague-Dawley rats were first treated with risperidone (1.0 mg/kg, sc) or sterile water and tested in the CAR model for 5 consecutive days from postnatal days P 40 to 44. After they became adults (~P 80-84), they were switched to olanzapine (0.5 mg/kg, sc), clozapine (5.0 mg/kg, sc) or vehicle treatment and tested for avoidance for 5 days. During the adolescent period, repeated risperidone treatment produced a persistent inhibition of avoidance response. Throughout the 5 days of adulthood drug testing, rats previously treated with risperidone in adolescence made significantly fewer avoidance responses than the vehicle ones when they all were switched to olanzapine, indicating a risperidone-induced enhancement of behavioral sensitivity to olanzapine. In contrast, when switched to clozapine, rats previously treated with risperidone made significantly more avoidance responses than the vehicle rats, indicating a risperidone-induced decrease of behavioral sensitivity to clozapine. Performance in the prepulse inhibition of acoustic startle response in adulthood was not altered by adolescent risperidone treatment. Collectively, adolescent risperidone exposure induced a long-term change in behavioral sensitivity to other atypical antipsychotic drugs, with the specific direction of change (i.e., increase or decrease) dependent on the drug to be switched to. These long-lasting changes are likely mediated by drug-induced neuroplastic changes and may also have significant clinical implications for antipsychotic treatment of chronic patients with an early onset of psychotic symptoms.
Introduction
Adolescence (human: 10-19 years old; rats: 35-60 days old) (Andersen et al., 2000) is a period in which the brain and various psychological functions undergo dramatic transitions. It is also the time when symptoms of a variety of severe mental disorders often manifest. Accumulating evidence indicates that adolescents may have enhanced sensitivity to psychotropic drugs (Findling et al., 2010; Kumra et al., 2008; Sikich et al., 2008) , and pharmacological interventions during this period alter brain structure and function in ways that are detectable at multiple levels (Singh and Chang, 2012) . Such alterations are often long-lasting and could alter the trajectory of the brain and behavioral development of pediatric patients, which in turn may change their later response to drug treatment as adults. As pediatric treatment is administered at a critical period of rapid brain and behavioral development, there is a crucial need to evaluate the possible long-term impacts of antipsychotic medications in adolescence on psychological functions and drug response, and to identify the neurobiological mechanisms.
In recent years, we have focused our attention on the issue of how early antipsychotic exposure in adolescence modifies later behavioral responsiveness to antipsychotic re-exposure in adulthood (Qiao et al., 2013) . We have used the conditioned avoidance response (CAR) model, a validated animal test of antipsychotic activity (Wadenberg and Hicks, 1999) , to examine this issue. The general approach follows our adult CAR work which involves two phases of drug effect assessment: an induction phase and an expression phase (Feng et al., 2013; Li et al., 2010 Li et al., , 2012b Mead and Li, 2010; Swalve and Li, 2012; Zhang and Li, 2012) . In the induction phase, rats are repeatedly treated Abbreviations: BrdU, 5′-Bromo-2-deoxyuridine; CAR, conditioned avoidance response; CLZ, clozapine; CLZ 5.0, clozapine 5.0 mg/kg; CS, conditioned stimulus; DA, dopamine; FDA, Food and Drug Administration; GABA, gamma amino butyric acid; OLZ, olanzapine; OLZ 0.5, olanzapine 0.5 mg/kg; P, postnatal; PCP, phencyclidine; PFC, prefrontal cortex; PPI, prepulse inhibition; sc, subcutaneously; RIS, risperidone; RIS 1.0, risperidone 1.0 mg/kg; VEH, vehicle; US, unconditioned stimulus; % PPI, percent prepulse inhibition. 
